Healthcare Sector Review: AmerisourceBergen CFO Leaves Company, Regeneron
Regeneron Pharmaceuticals (NASDAQ:REGN) has filed an sBLA for EYLEA in central retinal vein occlusion, or CRVO, in the U.S., and was granted a Prescription Drug User Free Act, or PDUFA, date of September 23, 2012. Bayer HealthCare plans to submit a similar regulatory application outside the U.S. in 2012 or early 2013.
The shares closed at $114.65, up $12.57, or 12.31%, on the day. Its market capitalization is $10.61 billion.
Chelsea Therapeutics’ (NASDAQ:CHTP) CEO to provide update at upcoming presentation.
The shares closed at $3.11, down $1.88, or 37.68%, on the day. Its market capitalization is $192.35 million.
AmerisourceBergen Corp. (NYSE:ABC) announced that Michael D. DiCandilo, the Company’s Executive Vice President and CFO, has left the Company to pursue other interests, effective immediately. Also effective immediately, Tim G. Guttman, the Company’s VP and Corporate Controller since 2002, will serve as acting CFO and will assume responsibility for the Company’s core financial functions on an interim basis. AmerisourceBergen has engaged an executive search firm to manage the recruitment of a new CFO.
The shares closed at $37.21, down $1.39, or 3.6%, on the day. Its market capitalization is $9.59 billion.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.